Target intelligence / Profile preview

Off-target genomic DNA loci (Prime Editing) (Off-target sites)

Target
Off-target sites
Molecular classification
Genomic DNA, Nucleic acid
01

Overview

Genomic DNA loci with partial complementarity to the PE3max pegRNA or nicking sgRNA refer to unintended sites in the genome where prime editing components may bind and exert activity. Prime editing (PE) utilizes a Cas9 nickase fused to a reverse transcriptase, guided by a prime editing guide RNA (pegRNA) and often an auxiliary nicking sgRNA in PE3 or PE3max systems to install precise genetic changes (Anzalone et al., 2019, Nature). Although prime editing is generally considered more precise than standard CRISPR-Cas9, the guide RNAs can still hybridize with off-target sequences that possess high sequence homology to the intended target (Kim et al., 2020, Nature Biotechnology). Interaction at these loci can result in permanent, unintended mutations, including insertions, deletions, or substitutions, which may disrupt tumor suppressor genes or activate oncogenes (Chen et al., 2021, Cell). These off-target effects represent a significant hurdle in the development of safe gene therapies, as they can lead to unpredictable cellular phenotypes or long-term genotoxicity. Monitoring these loci using high-throughput sequencing methods is essential for assessing the specificity of a prime editing therapeutic (Doman et al., 2020, Nature Biotechnology). Consequently, identifying and characterizing these loci is a fundamental requirement for the clinical development of prime editing therapies to ensure genomic integrity and patient safety.

Other names
Off-target genomic locipegRNA off-targetsNicking sgRNA off-targetsUnintended genomic modificationsPrime editing off-target effects
02

Mechanism of action

Unintended hybridization of guide RNAs to genomic sequences with partial complementarity, leading to Cas9-mediated DNA nicking and subsequent reverse transcription or DNA repair-mediated mutagenesis at non-target sites.

03

Biological functions

Genetic information storageTemplate for transcription
04

Disease associations

OncogenesisGenotoxicityGenetic disorders
05

Safety considerations

GenotoxicityInsertional mutagenesisChromosomal instabilityUnintended gene knockoutOncogenic transformation
06

Interacting drugs

Prime Editor 3 max (PE3max)

2 more in the full profile.

07

Biomarkers

Off-target mutation frequencyIndel formation rateChromosomal translocation frequencyCIRCLE-seq enrichmentGUIDE-seq read counts

Beyond the preview

Go deeper on Off-target genomic DNA loci (Prime Editing) (Off-target sites).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Off-target genomic DNA loci (Prime Editing) (Off-target sites).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call